Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens

Xiao, X; Chen, W; Feng, Y; Zhu, Z; Prabakaran, P; Wang, Y; Zhang, MY; Longo, NS; Dimitrov, DS

Biochemical And Biophysical Research Communications, 2009, v. 390 n. 3, p. 404-409

2009

http://hdl.handle.net/10722/65599

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens

Xiaodong Xiao, Weizao Chen, Yang Feng, Zhongyu Zhu, Ponraj Prabakaran, Yanping Wang, Mei-Yun Zhang, Nancy S. Longo, Dimitar S. Dimitrov

Introduction

Potent broadly cross-reactive neutralizing antibodies (bnAbs) are relatively rarely found in patients with HIV-1 infection. Possible causes include protection of conserved structures of the virus envelope glycoprotein (Env) by variable loops, extensive glycosylation, occlusion within the oligomer, and conformational masking, as well as the rapid generation of HIV-1 mutants that outpace the development of such antibodies and immunoregulatory mechanisms.[1–4]

The Env is immunogenic and a number of Env-specific hmAbs have been identified[5]. However, only several hmAbs, including IgG B12[6,7], IgG 2G12[8–10], and IgG 2F5[11], have been extensively characterized[3,12] and found to exhibit relatively potent and broad neutralizing activity to isolates from different clades. The existence of these antibodies has fueled the hope that the development of efficacious HIV vaccine is achievable provided that an immunogen containing the epitopes of these antibodies is appropriately designed. However, in spite of the large amount of research an antibody-based vaccine capable of eliciting broadly neutralizing antibodies has not been achieved[13].

Early studies have found relatively extensive antigen-driven maturation and non-restricted use of the V genes in several
HIV-specific antibodies [14–17]. Later, an analysis of non-neutralizing HIV gp41-specific human antibodies showed an average mutation frequency of approximately 10% [18]. A more recent study of the gene usage and extent of maturation of CD4-induced (CD4i) antibodies suggested a restricted VH1-69 gene usage for CD4i antibodies with long CDR3 and VH1-24 for CD4i antibodies with short CDR3s [19]. It was noted in this study that two of the best characterized anti-gp120 bnAbs, b12 and 2G12, have nearly 2-fold higher somatic hypermutation (about 20% mutation frequency) than other gp120-reactive antibodies analyzed in the study (Table 1 in [19]).

We have hypothesized that the high divergence of the known bnAbs from their corresponding germline antibodies may indicate that the germline antibodies lack the capability to bind to the epitopes of the mature antibodies. We designed germline-like antibodies corresponding to b12, 2G12, and 2F5 as well as to several human HIV-1-specific hmAbs (X5 [20], m44 [21], and m46 [22]). Fab X5 is a potent CD4i bnAbs but as a full-size (IgG1) antibody exhibits on average significantly decreased potency likely due to size-restricted access to its epitope [23]. IgG1 m44 and IgG1 m46 are gp41-specific cross-reactive HIV-1-neutralizing hmAbs with relatively modest potency. We found that germline-like b12, 2G12 and 2F5 did not bind to any of the EnvS although the corresponding mature antibodies did bind with relatively high level of activity. In contrast the germline-like X5, m44, and m46 bound with relatively high affinity to all tested EnvS. These results provide initial evidence that germline-like antibodies corresponding to known bnAbs antibodies may not be capable of binding to the Env to initiate and/or maintain an immune response leading to their elicitation in vivo.

Materials and methods

Proteins. Bal gp120-CD4 was provided by Tim Fouts (University of Maryland, Baltimore, MD) and other recombinant proteins (gp120s and gp140s) were provided by Christopher Broder (USUHS, Bethesda, MD).

Analysis of antibody sequences and design of germline-like antibodies. The heavy and light chain nucleotide sequences were analyzed with JoinSolvEr [24]. The mAb V(D)J alignments were assigned to the germline gene that yielded the fewest nucleotide mismatches. Values of p < 0.05 were used to compare D segment alignments to that expected from random chance. The minimum requirement for D segment alignment was 9 or 10 (depending on the length of the V to J region) matching nucleotides and at least 2 additional matches for each mismatch. Germline-like sequences were determined by reverting mutations to the germline sequence while retaining the original CDR3 junctions and terminal deoxynucleotidyl transferase (TdT) N nucleotides.

Gene synthesis and expression plasmid constructions. ScFv DNAs corresponding to mature and germline-like X5, m44, m46, b12, 2G12, and 2F5 were synthesized by Genescript (Genescript, Piscataway, NJ) and their accuracies were confirmed by sequencing. The VH of each of the antibodies was followed by a (GGGGS)3 linker and the VL SfiI restriction site was added to both N and C termini for each scFv during gene synthesis for cloning into pCOM3X plasmid (provided by Dennis Burton, Scripps Institute, La Jolla, CA) for expression in bacteria. The pCOM3X vector adds a His tag to the C terminus of each inserted scFv. The His tag was used subsequently for scFv purification and detection in ELISA. The DNA fragments encoding selected scFv proteins were fused with Fc of human IgG1 and cloned into the mammalian cell expression vector pSecTag2B (Invitrogen, Carlsbad, CA) for expression of the fusion proteins.

Antibody expression and purification. For scFv expression, Escherichia coli strain HB2151 was transformed by the scFv constructs described above. A single clone was inoculated into 2YT supplemented with 100 U of ampicillin, 0.2% glucose and incubated at 37 °C with shaking. When the OD600 reached 0.9, IPTG was added to achieve a final concentration of 1 mM and the culture continued overnight at 30 °C with shaking. Cells were then collected, lysed with polymyxin B (Sigma, St. Louis) in PBS, and the supernatant was subjected to the Ni-NTA agarose bead (Qiagen, Hilden, Germany) purification for the soluble scFvs. The scFv-Fc constructs were transfected into the 293 Freestyle cells with polyfectin transfection agent (Invitrogen). Four days after transfection, the culture medium was collected and the secreted scFv-Fc proteins were purified using a protein-A Sepharose column (GE Healthcare, Piscataway, NJ).

ELISA. Protein antigens diluted in PBS buffer in concentrations ranging from 1 to 4 μg/ml were added to the 96 well plate and left at 4 °C overnight to coat the plate. The plate was then blocked with PBS + 5% dry milk buffer. ScFv and scFv-Fc in different concentrations were diluted in the same blocking buffer and applied to the ELISA plate. The mouse-anti-His-HRP was used to detect the His tag at the C terminus of each of the scFv clones and the mouse-anti-human Fc-HRP was used to detect the Fc tag of the scFv-Fcs in most of the ELISA unless indicated otherwise. The HRP substrate ABTS (Roche, Mannheim, Germany) was then added to each well and OD 405 was taken 5–10 min afterward.

Results

High divergence of HIV-1-neutralizing hmAbs from germline antibodies

We have identified and characterized a number of hmAbs against HIV-1 some of which exhibit cross-reactive neutralizing activity against primary isolates from different clades [21,22,25–32] as well as a number of hmAbs against the SARS CoV [33,34], Hendra and Nipah viruses [35–37]. One of the antibodies (m396) potently neutralizes SARS CoV isolates from humans and animals [34] and others (m102 and m102.4) both henipaviruses, Nipah and Hendra [35,36]. The identification of many hmAbs against various infectious agents has provided an opportunity to analyze and compare their antibody sequences.

We identified the closest germline Ig genes and calculated the antibody gene divergence as the number of amino acid changes from the corresponding germline antibodies (using mostly the VH gene for comparison). We found that all of our HIV-1-specific antibodies and three bnAbs with publicly available DNA sequences, b12, 2G12 and 2F5, were hypermutated more than normal donor memory B cells which average 13 mutations per VH sequence [38] (Table 1 and data not shown). In contrast, the antibodies against SARS CoV and henipaviruses including m396, m102, and m102.4 had only several mutations from the closest germline (on average < 5%, data not shown). Potent antibody against a bacterial pathogen (Yersinia pestis) also had relatively low (3%) number of mutations (Xiao et al., unpublished). These results indicate that bnAbs against HIV-1 are significantly more divergent from the closest germline antibodies than hmAbs against SARS CoV and henipaviruses with potent and broad neutralizing activity.

Design of germline-like X5, m44, m46, b12, 2G12, and 2F5

To test whether the closest germline-like antibodies that presumably initiated the hypermutation process can bind the Env, we designed corresponding germline-like antibodies (Table 1). Because of the diversity of the D segment in the heavy chain CDR3 (H3) of m44, m46, b12, and 2G12 the germline sequence could not be determined with 95% confidence and the original D segment amino acid sequence was used for synthesizing the germline-like Ab.
To explore the hypothesis that some germline antibodies against conserved epitopes may not bind structures containing epitopes of their corresponding mature antibodies we synthesized the genes for six germline-like antibodies in a scFv format. The purified scFvs were tested for binding in an ELISA assay where recombinant Envs (gp140s) were used as target antigens. We observed high affinity binding of germline-like X5 and lower affinity binding for the germline-like antibodies m44 and m46 (Fig. 1). In contrast, there was no measurable binding for the germline-like antibodies b12, 2G12, and 2F5 even at very high (μM range) concentrations (Fig. 3). As expected, due to avidity effects the binding of the Fc fusion proteins with germline-like m44 and m46 was enhanced (Fig. 4). These results demonstrate that the germline-like antibodies corresponding to these three antibodies do not bind to recombinant gp140 in our ELISA assay even at high concentrations.

Discussion

We and others [19] have found that a number of HIV-1-specific neutralizing antibodies have unusually high frequencies of somatic hypermutation. The increase in somatic hypermutation was associated with an increase in nonsynonymous amino acid substitutions. In contrast, the neutralizing hmAbs against several viruses causing acute infections contain fewer amino acid substitutions. Notably, the potent bnAbs against SARS CoV and henipaviruses were selected by screening a large non-immune antibody library derived from ten healthy volunteers against the respective Env, as a method for resembling to a certain extent in vivo immunization [39]. To mimic better the B cells that respond to primary immunization, the heavy chains of the antibodies in this library from normal donors were of a type corresponding to IgM* B cells. When the same library and screening methodology was used against HIV-1 Envs, only weakly neutralizing non-cross-reactive antibodies resulted (data not shown). Panning with another IgM library from large number of healthy individuals resulted in non-neutralizing or even infection-enhancing antibodies (Chen et al., submitted). Previous Q1 attempts to select HIV-specific antibodies from non-immune li-

![Table 1](image)

Germ line-like scFvs X5, m44, and m46 bind but b12, 2G12, and 2F5 lack measurable binding to Envs

<table>
<thead>
<tr>
<th>Ab chain</th>
<th>V</th>
<th>D</th>
<th>J</th>
<th>CDR3 sequence</th>
<th>V segment mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>X5 HC</td>
<td>IGHV1-69*01</td>
<td>IGHD3-22*01</td>
<td>IGHJ4*02</td>
<td>GCC AGA GAT TTT GCC CCC GAC TGG GAA GAC GGT GAT TAC</td>
<td>27</td>
</tr>
<tr>
<td>X5 LC</td>
<td>IGRK3-20*01</td>
<td>—</td>
<td>IGHJ4*02</td>
<td>TAT GAT AGT AGC CGG GGG TTC TTT GAC TAC</td>
<td>13</td>
</tr>
<tr>
<td>m44 HC</td>
<td>IGHV4-61*01</td>
<td>IGHD3-10*02</td>
<td>—</td>
<td>GCG CCA GGA ACT GGG GGT TAC CTT TAC TTT TAC GAC TAC</td>
<td>42</td>
</tr>
<tr>
<td>m44 LC</td>
<td>IGHV4-34*01</td>
<td>IGHD5-12*01</td>
<td>—</td>
<td>GCG GCA GGA ACT GGG GGT TAC CTT TAC TTT TAC GAC TAC</td>
<td>24</td>
</tr>
<tr>
<td>m46 HC</td>
<td>IGKV1-9*01</td>
<td>IGHD3-10*02</td>
<td>IGKJ101</td>
<td>GCA GCA GTG GGG CCA TAT AGT TGC GAT TAC</td>
<td>36</td>
</tr>
<tr>
<td>m46 LC</td>
<td>IGKV1-3*01</td>
<td>IGHD3-10*02</td>
<td>IGKJ101</td>
<td>GCA GCA GTG GGG CCA TAT AGT TGC GAT TAC</td>
<td>20</td>
</tr>
<tr>
<td>b12 LC</td>
<td>IGKV1-3*01</td>
<td>IGHD3-10*02</td>
<td>IGKJ101</td>
<td>GCA GCA GTG GGG CCA TAT AGT TGC GAT TAC</td>
<td>35</td>
</tr>
<tr>
<td>2G12 HC</td>
<td>IGHV3-21*01</td>
<td>IGHD4 family</td>
<td>IGKJ3*01</td>
<td>GCA GCA AAG GCA TCT GAC ACA CTG ACT</td>
<td>60</td>
</tr>
<tr>
<td>2G12 LC</td>
<td>IGKV1-5*03</td>
<td>—</td>
<td>IGKJ101</td>
<td>GCA GCA AAG GCA TCT GAC ACA CTG ACT</td>
<td>34</td>
</tr>
<tr>
<td>2F5 HC</td>
<td>IGKV2-10*10</td>
<td>IGHD3-03*01</td>
<td>IGKJ102</td>
<td>GCA CAC CGA GGG CCA ACC ACA CTC TTT GCA</td>
<td>40</td>
</tr>
<tr>
<td>2F5 LC</td>
<td>IGKV1-3<em>01 or 1D-13</em>01</td>
<td>—</td>
<td>IGKJ4*01</td>
<td>GCA CAC TTT AAT AGT TAC CCT CAC ACT</td>
<td>34</td>
</tr>
</tbody>
</table>

* The best D alignment has >5% probability that the D match is a random match.
* The best D segment alignment for m44 is to the inverted (R) IGHD5-12*01 germline gene.
* An individual D4 gene could not be identified.

![Fig. 1](image)

Detectable bindings of germline-like X5, m44, and m46 antibodies in scFv format to Env. Bal gp120-CD4 fusion protein was coated on a 96 well ELISA plate for detection of scFv X5 binding, whereas 89.6 gp140 was coated for detection of scFv m44 and m46 bindings at indicated concentrations. Mature and germline-like antibodies were compared.

libraries have also resulted in antibodies with modest neutralizing activity and limited breadth of neutralization\cite{40,41}. These results indicate that HIV-1 has developed a strategy to protect its highly conserved epitopes against initial immune responses. In contrast, SARS CoV and henipaviruses appear to lack such a mechanism and their EnvS contain exposed, conserved receptor binding sites that can bind IgM + B cells with sufficient affinity to induce class switch and affinity maturation. Therefore, unlike HIV-1, Env-based vaccine immunogens and in particular the receptor binding domains of SARS CoV and henipaviruses can be highly effective in eliciting bnAbs.

Further support for this line of reasoning is our finding that germline-like b12, 2G12, and 2F5 lack measurable binding to Envs. We have not detected binding at relatively high (up to 10 μM) antibody concentrations. Although in general the threshold for B cell activation is believed to be on the order of μM equilibrium dissociation constants, it was demonstrated that even lower affinity/avidity interactions can trigger B cell activation in mice\cite{42,43}. However, even if binding occurs with very low avidity activated B cells expressing such BCRs are likely to be outcompeted by B cells expressing BCRs that bind to other epitopes with higher affinity/avidity. Such epitopes include those of X5 as a representative of a CD4i epitope and m44 and m46 as representatives of gp41 epitopes. X5 and other CD4i antibodies target a highly conserved and immunogenic structure overlapping with the coreceptor binding site; such antibodies are abundant in patients with HIV-1 infection\cite{44}. It has been demonstrated that the differences in responses of high and low affinity B cells can be relatively small but in competition experiments only the high-affinity B cells respond to antigen\cite{45,46}. One can hypothesize that during lengthy

Fig. 2. Lack of binding of germline-like b12, 2G12, and 2F5 antibodies in scFv format. Bal gp120 was coated for detection of b12 binding and 89.6 gp140 was coated for detection of binding by both scFv 2G12 and 2F5. Mature and germline-like formats were compared.

Fig. 3. Lack of binding of germline-like b12, 2G12, and 2F5 antibodies in Fc fusion protein format to Env. Bal gp120 was coated for detection of mature and germline-like scFv-Fc b12 binding and 89.6 gp140 was coated for detection of binding by mature scFv and germline-like scFv-Fc 2G12 and 2F5.

Fig. 4. Detectable bindings of germline-like m44 and m46 antibodies in Fc fusion protein format to Env. Env 89.6 gp140 was coated for detection of binding by scFv-Fc m44 and m46 fusion proteins.
chronic infections, HIV has evolved mechanisms to protect its most vulnerable but functionally important conserved structures including the CD4 binding site, conserved carbohydrates and gp41 membrane proximal external region (MPER) by using “holes” in the human germline BCR repertoire, i.e., these structures do not bind or bind very weakly to germline antibodies. At the same time HIV has evolved other structures which are either not accessible for full-size antibodies (e.g. some CD4i epitopes including the X5 one) or are not functionally important but can bind with relatively high affinity to B cells expressing germline antibodies that can out-compete those B cells expressing BCRs against conserved epitopes, if any.

In conclusions, the results indicate another possible mechanism used by HIV-1 to evade neutralizing immune responses. HIV-1 may be able to protect its vulnerable exposed conserved epitopes by using “holes” in the human germline repertoire. Germline BCRs that can recognize these epitopes and initiate and/or maintain immune responses by competing with BCRs that bind to other non-essential or non-accessible epitopes with high affinity may be missing from the naive repertoire. We would like to emphasize that this study is only an initial attempt to explore this possible mechanism and much more work is needed to prove it and to use the knowledge gained for the design of effective vaccine immunogens capable of eliciting potent bnAbs against HIV-1.

Acknowledgments

We thank Ruth Ruprecht, Hana Golding, Robert Blumenthal, Christopher Broder, Jorge Flores, Helen Quill, Nancy Miller, Garnett Kelsoe, and Barton Haynes for stimulating discussions and suggestions, Christopher Broder, Gerald Quinnan, Barton Haynes, Dennis Burton, and Tim Fouts for providing reagents, and John Owen for help. This work was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, by Federal funds from the NIH, National Cancer Institute, under Contract No. NO1-CO-12400, and by the Gates Foundation to D.S.D.

References


